ENDPOINTS NEWS40m
MaaT Phar­ma touts ‘un­prece­dent­ed’ Phase 3 ef­fi­ca­cy of graft-ver­sus-host dis­ease treat­ment
French biotech MaaT Pharma says its acute graft-versus-host disease treatment exceeded expectations in a single-arm Phase 3 ...
ENDPOINTS NEWS1h
Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago
Baby with genetic OTC deficiency shows promising response to iECURE's first-in-kind gene therapy, potentially avoiding liver ...